Russian officials have announced that a cancer vaccine named Enteromix has completed preclinical trials, claiming “high efficacy” and safety for repeated use, according to reports from state media. Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), revealed the development at the Eastern Economic Forum in Vladivostok, stating the vaccine is “now ready for use” pending official approval.

The vaccine targets colorectal cancer and has shown “promising progress” in trials, with preliminary results suggesting 100% efficacy in animal models, though these claims remain unverified by independent sources. Skvortsova emphasized that preclinical studies confirmed the vaccine’s safety, but experts caution that animal trial success does not guarantee human effectiveness.

Dr. David James Pinato, a medical oncologist at Imperial College London, highlighted the limitations of preclinical data, noting that results in rodents often fail to translate to humans due to differences in immune systems and cancer complexity. “The fact that a vaccine approach has had 100% efficacy in animals means absolutely nothing,” he said.

Russian media also reported advancements in vaccines for glioblastoma and melanoma, though no human trial data has been released. The FMBA stated these projects are in “advanced stages of development.”

No independent verification of the vaccine’s claims has been publicly disclosed, leaving questions about its readiness for mass deployment.